SG11201809494VA - Pharmaceutical composition comprising eteplirsen - Google Patents
Pharmaceutical composition comprising eteplirsenInfo
- Publication number
- SG11201809494VA SG11201809494VA SG11201809494VA SG11201809494VA SG11201809494VA SG 11201809494V A SG11201809494V A SG 11201809494VA SG 11201809494V A SG11201809494V A SG 11201809494VA SG 11201809494V A SG11201809494V A SG 11201809494VA SG 11201809494V A SG11201809494V A SG 11201809494VA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- pct
- eteplirsen
- street
- pharmaceutical composition
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Physical Education & Sports Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property 11111110111101110101011111010111110 011111111111101a 11101111111011 1111111 Organization 0 International Bureau (10) International Publication Number (43) International Publication Date .....0\"\" WO 2017/213854 Al 14 December 2017 (14.12.2017) WIP0 I PCT (51) International Patent Classification: A61K 31/7125 (2006.01) A61P 21/00 (2006.01) (21) International Application Number: PCT/US2017/034265 (22) International Filing Date: 24 May 2017 (24.05.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/340,947 24 May 2016 (24.05.2016) US 62/429,160 02 December 2016 (02.12.2016) US (71) Applicant: SAREPTA THERAPEUTICS, INC. [US/US]; 215 First Street, Cambridge, MA 02142 (US). (72) Inventor: HOLT, Thomas; c/o Sarepta Therapeutics, Inc., 215 First Street, Cambridge, MA 02142 (US). (74) Agent: TRINQUE, Brian, C. et al.; Lathrop & Gage, LLP, 28 State Street, Boston, MA 02109 (US). Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, = (81) =_ — = HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, = KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, __ MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, _ — = PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. = = Designated States (unless otherwise indicated, for every = (84) = = kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). = = _ _ = = = = = Published: — with international search report (Art. 21(3)) Il 7r ir) GC M Il ei N (54) Title: PHARMACEUTICAL COMPOSITION COMPRISING ETEPLIRSEN 1-1 0 (57) : Provided herein are pharmaceutical compositions comprising Eteplirsen. Also provided herein are methods of treating ei a muscle disease in a subject in need thereof, comprising administering to the subject a pharmaceutical composition of the disclosure.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662340947P | 2016-05-24 | 2016-05-24 | |
| US201662429160P | 2016-12-02 | 2016-12-02 | |
| PCT/US2017/034265 WO2017213854A1 (en) | 2016-05-24 | 2017-05-24 | Pharmaceutical composition comprising eteplirsen |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201809494VA true SG11201809494VA (en) | 2018-12-28 |
Family
ID=59093599
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201809494VA SG11201809494VA (en) | 2016-05-24 | 2017-05-24 | Pharmaceutical composition comprising eteplirsen |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20190275072A1 (en) |
| EP (1) | EP3463390A1 (en) |
| JP (1) | JP2019516730A (en) |
| KR (1) | KR20190009343A (en) |
| CN (1) | CN109562123A (en) |
| AU (1) | AU2017278699A1 (en) |
| BR (1) | BR112018074299A2 (en) |
| CA (1) | CA3024178A1 (en) |
| CO (1) | CO2018013828A2 (en) |
| IL (1) | IL263040A (en) |
| MA (1) | MA45158A (en) |
| MX (1) | MX2018014129A (en) |
| SG (1) | SG11201809494VA (en) |
| TW (1) | TW201805002A (en) |
| WO (1) | WO2017213854A1 (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI541024B (en) | 2010-09-01 | 2016-07-11 | 日本新藥股份有限公司 | Antisense nucleic acid |
| US20220251551A1 (en) * | 2018-06-13 | 2022-08-11 | Sarepta Therapeutics, Inc. | Exon skipping oligomers for muscular dystrophy |
| EP4219717A3 (en) * | 2018-06-13 | 2023-12-20 | Sarepta Therapeutics, Inc. | Exon skipping oligomers for muscular dystrophy |
| US20210220386A1 (en) * | 2018-06-14 | 2021-07-22 | Sarepta Therapeutics, Inc. | Exon skipping oligomers and oligomer conjugates for muscular dystrophy |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5034506A (en) | 1985-03-15 | 1991-07-23 | Anti-Gene Development Group | Uncharged morpholino-based polymers having achiral intersubunit linkages |
| US5217866A (en) | 1985-03-15 | 1993-06-08 | Anti-Gene Development Group | Polynucleotide assay reagent and method |
| US5166315A (en) | 1989-12-20 | 1992-11-24 | Anti-Gene Development Group | Sequence-specific binding polymers for duplex nucleic acids |
| US5506337A (en) | 1985-03-15 | 1996-04-09 | Antivirals Inc. | Morpholino-subunit combinatorial library and method |
| US5185444A (en) | 1985-03-15 | 1993-02-09 | Anti-Gene Deveopment Group | Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages |
| US5521063A (en) | 1985-03-15 | 1996-05-28 | Antivirals Inc. | Polynucleotide reagent containing chiral subunits and methods of use |
| ATE171185T1 (en) | 1985-03-15 | 1998-10-15 | Antivirals Inc | POLYNUCLEOTIDE IMMUNOTESTING AGENTS AND METHODS |
| EP0433345B1 (en) | 1988-09-01 | 1994-04-20 | Forskningscenter Riso | Peptide synthesis method and solid support for use in the method |
| ATE498685T1 (en) | 2004-06-28 | 2011-03-15 | Univ Western Australia | ANTISENSE OLIGONUCLEOTIDES FOR INDUCING EXON SKIPPING AND METHOD FOR THE USE THEREOF |
| US8067571B2 (en) | 2005-07-13 | 2011-11-29 | Avi Biopharma, Inc. | Antibacterial antisense oligonucleotide and method |
| US8299206B2 (en) | 2007-11-15 | 2012-10-30 | Avi Biopharma, Inc. | Method of synthesis of morpholino oligomers |
| US8076476B2 (en) | 2007-11-15 | 2011-12-13 | Avi Biopharma, Inc. | Synthesis of morpholino oligomers using doubly protected guanine morpholino subunits |
| WO2009064471A1 (en) | 2007-11-15 | 2009-05-22 | Avi Biopharma, Inc. | Method of synthesis of morpholino oligomers |
| PL2623507T3 (en) | 2010-09-30 | 2017-03-31 | Nippon Shinyaku Co., Ltd. | Morpholino nucleic acid derivative |
| US9944926B2 (en) | 2011-11-30 | 2018-04-17 | Sarepta Therapeutics, Inc. | Induced exon inclusion in spinal muscle atrophy |
| CN103933549A (en) * | 2013-01-17 | 2014-07-23 | 刘海俊 | Novel blood vessel chalone eye drop and preparation method thereof |
| CA2906812A1 (en) * | 2013-03-15 | 2014-09-18 | Sarepta Therapeutics, Inc. | Improved compositions for treating muscular dystrophy |
-
2017
- 2017-05-24 US US16/302,484 patent/US20190275072A1/en not_active Abandoned
- 2017-05-24 BR BR112018074299-6A patent/BR112018074299A2/en not_active Application Discontinuation
- 2017-05-24 CN CN201780030581.5A patent/CN109562123A/en active Pending
- 2017-05-24 KR KR1020187036635A patent/KR20190009343A/en not_active Application Discontinuation
- 2017-05-24 MX MX2018014129A patent/MX2018014129A/en unknown
- 2017-05-24 WO PCT/US2017/034265 patent/WO2017213854A1/en unknown
- 2017-05-24 EP EP17731957.1A patent/EP3463390A1/en not_active Withdrawn
- 2017-05-24 AU AU2017278699A patent/AU2017278699A1/en not_active Abandoned
- 2017-05-24 SG SG11201809494VA patent/SG11201809494VA/en unknown
- 2017-05-24 JP JP2018560674A patent/JP2019516730A/en active Pending
- 2017-05-24 CA CA3024178A patent/CA3024178A1/en not_active Abandoned
- 2017-05-24 MA MA045158A patent/MA45158A/en unknown
- 2017-05-24 TW TW106117190A patent/TW201805002A/en unknown
-
2018
- 2018-11-15 IL IL263040A patent/IL263040A/en unknown
- 2018-12-19 CO CONC2018/0013828A patent/CO2018013828A2/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3463390A1 (en) | 2019-04-10 |
| MX2018014129A (en) | 2019-04-29 |
| WO2017213854A1 (en) | 2017-12-14 |
| US20190275072A1 (en) | 2019-09-12 |
| CO2018013828A2 (en) | 2018-12-28 |
| TW201805002A (en) | 2018-02-16 |
| CA3024178A1 (en) | 2017-12-14 |
| CN109562123A (en) | 2019-04-02 |
| AU2017278699A1 (en) | 2018-11-15 |
| JP2019516730A (en) | 2019-06-20 |
| IL263040A (en) | 2018-12-31 |
| KR20190009343A (en) | 2019-01-28 |
| MA45158A (en) | 2019-04-10 |
| BR112018074299A2 (en) | 2019-03-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201809344QA (en) | Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde | |
| SG11201808990QA (en) | Compositions for topical application of compounds | |
| SG11201909960UA (en) | Methods for improving memory and cognition and for treating memory and cognitive disorders | |
| SG11201810420YA (en) | Antibodies to alpha-synuclein and uses thereof | |
| SG11201810280YA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201906436VA (en) | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | |
| SG11201909155VA (en) | Ask1 inhibitor compounds and uses thereof | |
| SG11201809499UA (en) | Processes for preparing phosphorodiamidate morpholino oligomers | |
| SG11201900554YA (en) | Spiro-lactam nmda modulators and methods of using same | |
| SG11201900558RA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201808222RA (en) | Methods of treatment of cholestatic diseases | |
| SG11201807597UA (en) | Methods of treating depression using orexin-2 receptor antagonists | |
| SG11201900551WA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201900546UA (en) | Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201907356SA (en) | Piperidine-substituted mnk inhibitors and methods related thereto | |
| SG11201808676RA (en) | Methods of treating pediatric cancers | |
| SG11201811559WA (en) | Cancer treatment combinations | |
| SG11201806544XA (en) | Compounds and methods of treating rna-mediated diseases | |
| SG11201909224QA (en) | Benzoazepine analogs as inhibiting agents for bruton's tyrosine kinase | |
| SG11201809702SA (en) | Benzenesulfonamide compounds and their use as therapeutic agents | |
| SG11201805755SA (en) | Methods of administering hepcidin | |
| SG11201811686UA (en) | 18f-labeled triazole containing psma inhibitors | |
| SG11201809494VA (en) | Pharmaceutical composition comprising eteplirsen | |
| SG11201806127XA (en) | Pharmaceutical or nutritional combination comprising beta-hydroxy-betamethylbutyrate | |
| SG11201901048VA (en) | Pharmaceutical compositions and uses directed to lysosomal storage disorders |